Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study
Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S83
DOI: 10.1055/s-0044-1785400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Sean Wharton und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Does treatment with Orforglipron (OFG) achieve significant greater change in body weight (BW) and waist circumference (WC) from baseline compared to placebo (PBO)?
Methods
In this phase 2 study, participants (N=272) were randomized to placebo or OFG (12, 24, 36, or 45 mg) maintenance treatment. OFG doses were increased to target using different dose escalation schemes in each arm. The primary endpoint was to compare percent body weight (BW) change from baseline in OFG vs placebo at Week 26, with a secondary endpoint at 36 weeks. Secondary endpoints included also change from baseline in waist circumference (WC) and BMI, and the percentage of participants achieving ≥5 or ≥10% weight loss.
Results
At baseline, mean BW was 108.7 kg, BMI was 37.9 kg/m2, and 94% of participants had a BMI ≥30 kg/m2. Mean percentage BW loss, mean change in BMI and WC, and the percentage of participants achieving ≥5% or ≥10% weight loss were significantly greater with all OFG doses vs placebo. The AE profile was similar to other GLP-1 RAs; most were GI-related and mild to moderate in severity.
Conclusion
The novel non-peptide GLP-1 receptor agonist OFG led to greater reductions in BW, BMI, and WC compared with placebo. These promising data support continued development of OFG as an oral treatment for obesity. Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Mather, K. J., Haupt, A., Robins, D., Pratt, E., Kazda, C., Konig, M., & Forst, T. (2024). Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study. Diabetologie und Stoffwechsel, 19(S 01 S 01), S83. https://doi.org/10.1055/s-0044-1785400
Vancouver
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Mather KJ, et al. Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study. Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S83. doi:10.1055/s-0044-1785400
BibTeX
@article{Wharton2024,
author = {Wharton, Sean and Blevins, Thomas and Connery, Lisa and Rosenstock, Julio and Raha, Sohini and Mather, Kieren J. and Haupt, Axel and Robins, Deborah and Pratt, Edward and Kazda, Christof and Konig, Manige and Forst, Thomas},
title = {Effect of oral non-peptide GLP-1 receptor agonist orforglipron (LY3502970) in participants with obesity or overweight: A Phase 2 study},
journal = {Diabetologie und Stoffwechsel},
year = {2024},
volume = {19},
number = {S 01 S 01},
pages = {S83},
doi = {10.1055/s-0044-1785400}
}
EUVIMED